Prof. Hideyuki Akaza

The University of Tokyo, Japan

Email: akazah@med.rcast.u-tokyo.ac.jp

Qualifications

1980  M.Sc., The University of Tokyo, Japan

1973  B.Sc., The University of Tokyo, Japan

Publications (Selected)

1. Sugimoto, M., Kakehi, Y., Horie, S., Hirao, Y., & Akaza, H. (2022). A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study. Japanese Journal of Clinical Oncology, 52(2), 187-196.
2. Onozawa, M., Hinotsu, S., Akaza, H., & Nakajima, T. (2021). Current Clinical Practice Pattern for Castration-Resistant Prostate Cancer (CRPC) in Japan. Gan to Kagaku ryoho. Cancer & Chemotherapy, 48(11), 1359-1363.
3. Lim, J., Malek, R., Toh, C. C., Sundram, M., Woo, S. Y., Yusoff, N. A., ... & M‐CaP Study. (2021). Prostate cancer in multi‐ethnic Asian men: Real‐world experience in the Malaysia Prostate Cancer (M‐CaP) Study. Cancer Medicine, 10(22), 8020-8028.
4. Uemura, H., Kobayashi, K., Yokomizo, A., Hinotsu, S., Horie, S., Kakehi, Y., ... & Akaza, H. (2022). Enzalutamide+ androgen deprivation therapy (ADT) versus flutamide+ ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study. BJUI compass, 3(1), 26-36.
5. Onozawa, M., Hinotsu, S., Saito, A., Uno, S., & Akaza, H. (2021). Primary Androgen-Depletion Therapy Prevails Not Only for Metastatic but Also for Nonmetastatic Hormone-Naïve Prostate Cancer in Japan-Recent Trends and Efficacy. Gan to kagaku ryoho. Cancer & chemotherapy, 48(7), 911-919.
6. Chikamatsu, S., Shiota, M., Onozawa, M., Hinotsu, S., Kitagawa, Y., Sakamoto, S., ... & Japan Study Group of Prostate Cancer (J‐CaP). (2021). Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi‐institutional Japan‐wide database. International Journal of Urology, 28(9), 927-935.
7. Blas, L., Onozawa, M., Shiota, M., Hinotsu, S., Sakamoto, S., Kitagawa, Y., ... & Japan Study Group of Prostate Cancer (J‐CaP). (2021). Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old. Cancer Science, 112(8), 3074-3082.
8. Shiota, M., Sumikawa, R., Onozawa, M., Hinotsu, S., Kitagawa, Y., Sakamoto, S., ... & Japan Study Group of Prostate Cancer (J‐CaP). (2021). Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi‐institutional Japan‐wide database. International Journal of Urology, 28(5), 584-591.
9. Uemura, H., Kobayashi, K., Yokomizo, A., Hinotsu, S., Horie, S., Kakehi, Y., ... & Akaza, H. (2021). Enzalutamide plus androgen deprivation therapy (ADT) versus flutamide plus ADT in men with castration-resistant prostate cancer (CRPC): AFTERCAB.
10. Lim, J., Hinotsu, S., Onozawa, M., Malek, R., Sundram, M., Teh, G. C., ... & Akaza, H. (2020). Modified J‐CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy. Cancer Medicine, 9(24), 9346-9352.
11. Inamoto, T., Azuma, H., Tatsugami, K., Oya, M., Adachi, M., Okayama, Y., ... & Akaza, H. (2020). Real-world use of sorafenib for advanced renal cell carcinoma patients with cardiovascular disease: nationwide survey in Japan. Expert Review of Anticancer Therapy, 20(7), 615-623.
12. Ikeda, A., Kojima, T., Kawai, K., Hinotsu, S., Keino, N., Shiga, K., ... & Nishiyama, H. (2020). Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan. International Journal of Clinical Oncology, 25, 1163-1169.
13. Shiota, M., Onozawa, M., Hinotsu, S., Eto, M., Naito, S., Akaza, H., & Japan Study Group of Prostate Cancer (J‐CaP). (2020). Family history in primary hormone therapy for prostate cancer: analysis from a community‐based multi‐institutional Japan‐wide database. International Journal of Urology, 27(4), 313-318.
14. Youl Lee, J. I., Taniguchi, T., Zhang, K., Ng, C. F., Hakim, L., Umbas, R., ... & Akaza, H. (2019). Report of the forth Asian Prostate Cancer (A-CaP) study meeting.
15. Shiota, M., Onozawa, M., Hinotsu, S., Eto, M., Naito, S., Akaza, H., & Japan Study Group of Prostate Cancer (J‐CaP). (2020). Family history in primary hormone therapy for prostate cancer: analysis from a community‐based multi‐institutional Japan‐wide database. International Journal of Urology, 27(4), 313-318.

Profile Details

https://en.wikipedia.org/wiki/Hideyuki_Akaza

https://www.researchgate.net/profile/Hideyuki-Akaza

https://www.linkedin.com/in/hideyuki-akaza-684a7339/